This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): Formoterol/Alvesco, XRP1526/AVE2635
Description: Ciclesonide/formoterol is a combination of the once-daily inhaled corticosteroid Alvesco (Ciclesonide) and the twice-daily inhaled beta-agonist formoterol. It is being formulated in a dried powder inhaler.
Deal Structure: The collaboration and development agreements related to a combination of ciclesonide and formoterol were terminated in 2007. All the corresponding development and commercial rights granted to sanofi aventis for the United States have been returned to Nycomed.
In May 2011, Takeda Pharmaceutical and Nycomed A/S jointly announced that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the company for 9.6 billion Euro on a cash-free, debt-free basis. The purchase would exclude Nycomed's U.S. dermatology business. The acquisition closed in September 2011.
Partners: Teijin Pharma Limited
Additional information available to subscribers only: